Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
INDOCO

Indoco Remedies Share Price

 

 

Indoco Remedies live price: ₹217.8. It opened at ₹216 vs previous close ₹219; intraday high/low: ₹222/₹215. The 50 & 200 DMA stand at ₹210.14/₹235.96.

Indoco Remedies Performance

  • Today's Low
  • ₹215
  • Today's High
  • ₹222
  • 52 Week Low
  • ₹162
  • 52 Week High
  • ₹350
  • Open Price₹216
  • Previous Close₹219
  • Volume81,718
  • 50 DMA₹210.14
  • 100 DMA₹217.41
  • 200 DMA₹235.96

Indoco Remedies Chart

Investment Returns

  • Over 1 Month + 7.6%
  • Over 3 Month + 6.28%
  • Over 6 Month -19.11%
  • Over 1 Year -9.69%

Smart Investing Starts Here Start SIP with Indoco Remedies for Steady Growth!

Invest Now

Indoco Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -21.1
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 2,010
  • P/B Ratio
  • 2.1
  • Average True Range
  • 11.68
  • EPS
  • 0
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 6.01
  • RSI
  • 52.86
  • MFI
  • 77.04

Indoco Remedies Financials

Indoco Remedies Technicals

EMA & SMA

Current Price
₹217.80
-1.12 (-0.51%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹215.70
  • 50 Day
  • ₹210.14
  • 100 Day
  • ₹217.41
  • 200 Day
  • ₹235.96

Resistance and Support

218.09 Pivot Speed
  • R3 228.80
  • R2 225.33
  • R1 221.56
  • S1 214.32
  • S2 210.85
  • S3 207.08

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Indoco Remedies Ltd. is a leading Indian pharmaceutical company specializing in the manufacturing and marketing of generic formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company focuses on quality, innovation, and compliance across various therapeutic segments.

Indoco Remedies has an operating revenue of Rs. 1,843.53 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of -6% needs improvement, ROE of -10% is poor and needs improvement. The company has a debt to equity of 55%, which is bit higher. The stock from a technical standpoint is trading below to its 200DMA and around 8% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 23 which is a POOR score indicating inconsistency in earnings, a RS Rating of 40 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 62 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Indoco Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-07 Audited Results & Final Dividend
2026-02-03 Quarterly Results
2025-11-06 Quarterly Results
2025-07-24 Quarterly Results
2025-05-22 Audited Results & Final Dividend
Date Purpose Remarks
2025-09-04 FINAL Rs.0.20 per share(10%)Final Dividend
View Indoco Remedies Dividend History Arrow

Indoco Remedies Shareholding Pattern

58.86%
17.54%
0.94%
16.56%
6.1%

Indoco Remedies FAQs

Indoco Remedies share price is ₹217 As on 13 May, 2026 | 01:50

The Market Cap of Indoco Remedies is ₹2010.4 Cr As on 13 May, 2026 | 01:50

The P/E ratio of Indoco Remedies is -21.1 As on 13 May, 2026 | 01:50

The PB ratio of Indoco Remedies is 2.1 As on 13 May, 2026 | 01:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23